Literature DB >> 27075768

Using miRNA-mRNA Interaction Analysis to Link Biologically Relevant miRNAs to Stem Cell Identity Testing for Next-Generation Culturing Development.

Marian A E Crabbé1, Kristel Gijbels2, Aline Visser2, David Craeye2, Sara Walbers2, Jef Pinxteren2, Robert J Deans3, Wim Annaert4, Bart L T Vaes5.   

Abstract

UNLABELLED: Therapeutic benefit of stem cells has been demonstrated in multiple disease models and clinical trials. Robust quality assurance is imperative to make advancements in culturing procedures to enable large-scale cell manufacturing without hampering therapeutic potency. MicroRNAs (miRNAs or miRs) are shown to be master regulators of biological processes and are potentially ideal quality markers. We determined miRNA markers differentially expressed under nonclinical multipotent adult progenitor cell (MAPC) and mesenchymal stem cell (MSC) culturing conditions that regulate important stem cell features, such as proliferation and differentiation. These bone marrow-derived stem cell types were selected because they both exert therapeutic functions, but have different proliferative and regenerative capacities. To determine cell-specific marker miRNAs and assess their effects on stem cell qualities, a miRNA and mRNA profiling was performed on MAPCs and MSCs isolated from three shared donors. We applied an Ingenuity Pathway Analysis-based strategy that combined an integrated RNA profile analysis and a biological function analysis to determine the effects of miRNA-mRNA interactions on phenotype. This resulted in the identification of important miRNA markers linked to cell-cycle regulation and development, the most distinctive being MAPC marker miR-204-5p and MSC marker miR-335-5p, for which we provide in vitro validation of its function in differentiation and cell cycle regulation, respectively. Importantly, marker expression is maintained under xeno-free conditions and during bioreactor isolation and expansion of MAPC cultures. In conclusion, the identified biologically relevant miRNA markers can be used to monitor stem cell stability when implementing variations in culturing procedures. SIGNIFICANCE: Human adult marrow stromal stem cells have shown great potential in addressing unmet health care needs. Quality assurance is imperative to make advancements in large-scale manufacturing procedures. MicroRNAs are master regulators of biological processes and potentially ideal quality markers. MicroRNA and mRNA profiling data of two human adult stem cell types were correlated to biological functions in silico. Doing this provided evidence that differentially expressed microRNAs are involved in regulating specific stem cell features. Furthermore, expression of a selected microRNA panel was maintained in next-generation culturing platforms, demonstrating the robustness of microRNA profiling in stem cell comparability testing. ©AlphaMed Press.

Entities:  

Keywords:  Bioreactor; Cell comparability testing; Mesenchymal stem cell; MicroRNA profiling; Multipotent adult progenitor cell; Xenobiotic-free

Mesh:

Substances:

Year:  2016        PMID: 27075768      PMCID: PMC4878327          DOI: 10.5966/sctm.2015-0154

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  74 in total

1.  Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells.

Authors:  Susan Kohlhaas; Oliver A Garden; Cheryl Scudamore; Martin Turner; Klaus Okkenhaug; Elena Vigorito
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

2.  MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells.

Authors:  Maurizio Ceppi; Patricia M Pereira; Isabelle Dunand-Sauthier; Emmanuèle Barras; Walter Reith; Manuel A Santos; Philippe Pierre
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-04       Impact factor: 11.205

3.  MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4.

Authors:  Ling Gao; Yijin Yang; Haiyan Xu; Ruqian Liu; Dechun Li; Han Hong; Mingde Qin; Yunliang Wang
Journal:  Tumour Biol       Date:  2014-05-24

Review 4.  The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming.

Authors:  Amar M Singh; Stephen Dalton
Journal:  Cell Stem Cell       Date:  2009-08-07       Impact factor: 24.633

Review 5.  Origins and Mechanisms of miRNAs and siRNAs.

Authors:  Richard W Carthew; Erik J Sontheimer
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

6.  MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells.

Authors:  Na Xu; Thales Papagiannakopoulos; Guangjin Pan; James A Thomson; Kenneth S Kosik
Journal:  Cell       Date:  2009-04-30       Impact factor: 41.582

7.  Mutual interaction between human multipotent adult progenitor cells and NK cells.

Authors:  Sandra A Jacobs; Jeroen Plessers; Jef Pinxteren; Valerie D Roobrouck; Catherine M Verfaillie; Stefaan W Van Gool
Journal:  Cell Transplant       Date:  2014       Impact factor: 4.064

8.  MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation.

Authors:  Jian Huang; Lan Zhao; Lianping Xing; Di Chen
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

9.  Epigenetic signatures associated with different levels of differentiation potential in human stem cells.

Authors:  Pablo Aranda; Xabier Agirre; Esteban Ballestar; Enrique J Andreu; José Román-Gómez; Inés Prieto; José Ignacio Martín-Subero; Juan Cruz Cigudosa; Reiner Siebert; Manel Esteller; Felipe Prosper
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer.

Authors:  Xin Yan; Xi Chen; Hongwei Liang; Ting Deng; Weixu Chen; Suyang Zhang; Minghui Liu; Xiujuan Gao; Yanqing Liu; Chihao Zhao; Xueliang Wang; Nan Wang; Jialu Li; Rui Liu; Ke Zen; Chen-Yu Zhang; Baorui Liu; Yi Ba
Journal:  Mol Cancer       Date:  2014-09-24       Impact factor: 27.401

View more
  7 in total

1.  Prenatal administration of multipotent adult progenitor cells modulates the systemic and cerebral immune response in an ovine model of chorioamnionitis.

Authors:  Luise Klein; Daan R M G Ophelders; Daniel van den Hove; Maurits Damoiseaux; Bart P F Rutten; Chris P M Reutelingsperger; Leon J Schurgers; Tim G A M Wolfs
Journal:  Brain Behav Immun Health       Date:  2022-05-02

2.  Obesity-induced mitochondrial dysfunction in porcine adipose tissue-derived mesenchymal stem cells.

Authors:  Yu Meng; Alfonso Eirin; Xiang-Yang Zhu; Hui Tang; Pritha Chanana; Amir Lerman; Andre J van Wijnen; Lilach O Lerman
Journal:  J Cell Physiol       Date:  2018-02-27       Impact factor: 6.384

Review 3.  Manufacturing of primed mesenchymal stromal cells for therapy.

Authors:  James Q Yin; Jun Zhu; James A Ankrum
Journal:  Nat Biomed Eng       Date:  2019-01-28       Impact factor: 25.671

4.  Human multipotent adult progenitor cell-conditioned medium improves wound healing through modulating inflammation and angiogenesis in mice.

Authors:  Parinaz Ahangar; Stuart J Mills; Louise E Smith; Xanthe L Strudwick; Anthony E Ting; Bart Vaes; Allison J Cowin
Journal:  Stem Cell Res Ther       Date:  2020-07-17       Impact factor: 6.832

5.  Alginate encapsulated multipotent adult progenitor cells promote corneal stromal cell activation via release of soluble factors.

Authors:  Olla Al-Jaibaji; Stephen Swioklo; Kristel Gijbels; Bart Vaes; Francisco C Figueiredo; Che J Connon
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Multipotent adult progenitor cells grown under xenobiotic-free conditions support vascularization during wound healing.

Authors:  Bart Vaes; Ellen Van Houtven; Ellen Caluwé; Aernout Luttun
Journal:  Stem Cell Res Ther       Date:  2020-09-07       Impact factor: 6.832

7.  Decellularized Articular Cartilage Microgels as Microcarriers for Expansion of Mesenchymal Stem Cells.

Authors:  Esmaiel Jabbari; Azadeh Sepahvandi
Journal:  Gels       Date:  2022-02-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.